ABBOTT LABORATORIES
$107.45
+0.20 (+0.19%) · delayed · Nov 16, 2026
Five-year price
52w $81.97 to $132.03
- Market cap
- $186.1B
- Enterprise value
- $190.5B
- P/E
- 28.9×
- 22.0× on 3y avg EPS
- EV / EBIT
- 23.7×
- FCF yield
- 4.0%
- ROIC
- 11.0%
- Debt / equity
- 0.25
- Piotroski F
- 5/9
Value scorecard · FY2025
Does it pass the value tests?
Quality
- ●ROIC > 12% (5y avg)5y avg ROIC 13.6%
- ●ROE > 15% (5y avg)5y avg ROE 18.8%
- ●Stable operating marginsMargin volatility 1.4% (σ, 5y)
- ●Earnings convert to cashFCF / net income 97% (5y avg)
- ●Growing revenueRevenue CAGR 5y 5.1%
- ●Shrinking share countDiluted shares -2.1% over 5y
Value
- ○P/E below 15P/E 28.9
- ○EV/EBIT below 12EV/EBIT 23.7
- ○FCF yield above 6%FCF yield 4.0%
- ○Price below Graham NumberGraham Number $50.19
- ○P/B below 3P/B 3.6
Safety
- ●Debt / equity below 0.5D/E 0.25
- ●Debt payable in < 4 yrs of earningsNet debt $4.4B
- ●Interest coverage > 8xCoverage 16.3x
- ●Current ratio > 1.5Current ratio 1.58
- ○Piotroski F-score ≥ 6F-score 5/9
Graham Defensive
- ●Adequate size (revenue > $2B)Revenue $44.3B
- ○Strong condition (current ratio ≥ 2)Current ratio 1.58
- ●Earnings stability (no loss, 10y)10 years of data
- ●Uninterrupted dividendsDividends paid every year on record
- ●Earnings growth ≥ 33% (10y, 3y avgs)EPS growth 476%
- ○Moderate P/E (≤ 15 on 3y avg EPS)P/E (3y avg) 22.0
- ○P/E × P/B ≤ 22.5Product 78.7
Valuation lab
What do you have to believe?
At $107.45, the market is pricing in about 9.0% annual free-cash-flow growth for the next decade (9% discount rate, 2.5% terminal growth).
Starting cash flow
Net debt $4.4B · 1732M shares · 5y revenue CAGR 5.1%
Intrinsic value
$78.75
Price
$107.45
Premium paid
36%
What the price implies
The market is paying for 9.0% annual cash-flow growth for 10 years at a 9.0% discount rate.
Terminal value share
57% of the value sits beyond year 10.
Financial statements
A decade of the record.
USD millions · fiscal years · source: SEC 10-K XBRL
| Line item | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20,853 | 27,390 | 30,578 | 31,904 | 34,608 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Operating income | 3,026 | 1,564 | 3,650 | 4,532 | 5,357 | 8,425 | 8,362 | 6,478 | 6,825 | 8,053 |
| Operating margin | 14.5% | 5.7% | 11.9% | 14.2% | 15.5% | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% |
| Pre-tax income | 1,413 | 2,231 | 2,873 | 4,077 | 4,968 | 8,211 | 8,306 | 6,664 | 7,013 | 8,466 |
| Income tax | 350 | 1,878 | 539 | 390 | 497 | 1,140 | 1,373 | 941 | (6,389) | 1,942 |
| Net income | 1,400 | 477 | 2,368 | 3,687 | 4,495 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 |
| EPS (diluted) | 0.94 | 0.27 | 1.33 | 2.06 | 2.50 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 |
| Diluted shares | 1,483 | 1,749 | 1,770 | 1,781 | 1,786 | 1,789 | 1,764 | 1,749 | 1,748 | 1,748 |
Who owns it